Brought to you by 
Watson gets rights to Itero's rFSH for female infertility
20 Aug 2010
Executive Summary
Watson Pharmaceuticals Inc. (generics and branded urology and women's health products) has received exclusive worldwide rights to Itero Biopharmaceuticals Inc.'s (protein therapeutics) recombinant follicle-stimulating hormone (rFSH), which is in preclinical studies for female infertility.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson gets rights to Itero's rFSH for female infertility
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice